Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 360.29B, Merck(MRK) trades at $145.89. The stock has a price-to-earnings ratio of 113.48 and currently yields dividends of 2.39%.
On 2026-10-14, Merck(MRK) stock traded between a low of $142.15 and a high of $145.97. Shares are currently priced at $145.89, which is +2.6% above the low and -0.1% below the high.
Merck(MRK) shares are trading with a volume of 1.9M, against a daily average of 8.58M.
During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.
During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.
MRK News
An update from Merck & Company ( (MRK) ) is now available. On Oct. 13, 2026, Merck & Co., Inc. announced that Paul J. Diaz, managing partner at private investm...
has had a powerful multiyear run, and with oncology news still coming thick and fast, the real issue for you now is whether the current share price lines up wit...
Merck (MRK) & Co. announced that Paul Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will st...
Analyst ratings
68%
of 31 ratingsMore MRK News
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating...
RBC Capital analyst Trung Huynh lowered the firm’s price target on Merck (MRK) to $145 from $150 and keeps a Sector Perform rating on the shares. The firm is re...
Merck (NYSE:MRK) reported one-year pivotal Phase 2b/3 BRUNELLO data for remigromig in diabetic macular edema. The tri-specific antibody met its primary endpoin...
Merck (MRK) announced the first presentation of one-year results from the pivotal Phase 2b/3 Brunello trial evaluating remigromig, an investigational, potential...
A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnolog...
Investing Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies Vaccine and biotechnology names are leading a sharp sector rally, and a smal...
Investing Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.